Brown, Lisle/Cummings, Inc. Novavax Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Novavax Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 90 shares of NVAX stock, worth $775. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90
Previous 90
-0.0%
Holding current value
$775
Previous $1.14 Million
0.18%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NVAX
# of Institutions
291Shares Held
93.4MCall Options Held
6.95MPut Options Held
9.4M-
Vanguard Group Inc Valley Forge, PA15.4MShares$133 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$102 Million0.0% of portfolio
-
Shah Capital Management9.82MShares$84.6 Million40.63% of portfolio
-
State Street Corp Boston, MA7.69MShares$66.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.94MShares$51.2 Million0.07% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $674M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...